Theoretically, blocking C5a receptor (C5aR) activity could form a therapeutic strategy for RA. The recently developed cyclic peptide AcF-[OpdChaWR] (PMX53) competes effectively with C5aR without ...

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and ...